|
ChemicalBook Optimization Suppliers |
|
| 化学名: | シタグリプチン | | 英語化学名: | Sitagliptin | | 别名: | Sitagliptin;(3R)-3-AMino-1-[3-(trifluoroMethyl)-5,6,7,8-tetrahydro-1,2,4-riazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-rifluorophenyl) butan-1-one;Sitagliptin-D4 HCL;Hsdb 7516;C53323300;Metformin / sitagliptin;Metformin hydrochloride mixture with sitagliptin phosphate;Metformin mixture with sitagliptin | | CAS番号: | 486460-32-6 | | 分子式: | C16H15F6N5O | | 分子量: | 407.31 | | EINECS: | 690-730-1 | | カテゴリ情報: | Heterocycles;Pharmaceutical intermediate;API;486460-32-6 | | Mol File: | 486460-32-6.mol |  |
| 融点 | 114.1-115.7 °C | | 沸点 | 529.9±60.0 °C(Predicted) | | 比重(密度) | 1.61±0.1 g/cm3(Predicted) | | 貯蔵温度 | Store at -20°C | | 溶解性 | DMSO : ≥ 50 mg/mL (122.76 mM) | | 酸解離定数(Pka) | 7.20±0.10(Predicted) | | InChI | InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1 | | InChIKey | MFFMDFFZMYYVKS-SECBINFHSA-N | | SMILES | C(N1CCN2C(C(F)(F)F)=NN=C2C1)(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F | | CAS データベース | 486460-32-6(CAS DataBase Reference) | | EPAの化学物質情報 | 1-Butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)-, (3R)- (486460-32-6) |
| | シタグリプチン Usage And Synthesis |
| 用途 | シタグリプチンリン酸塩水和物（シタグリプチンリンさんえんすいわぶつ、Sitagliptin Phosphate Hydrate）は、DPP-4 (Dipepeptidyl peptidase-4) 阻害薬に分類される経口血糖降下薬である。DPP-4はインクレチンの分解に関係する酵素であり、これを阻害することで、高血糖時のインスリン分泌を高めて血糖値を低下させるので、2型糖尿病の治療薬として利用されている。GLP-1アナログ製剤であるリラグルチドと同じくインクレチン関連薬の1つであり、SU剤に代表される経口血糖降下薬に比べて低血糖のリスクが少ないとされる。 | | 効能 | 糖尿病治療薬, DPP-4阻害薬 | | 説明 | Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is a first-in-class oral
drug launched for the treatment of type 2 diabetes. It acts by slowing the
inactivation of incretins, which are endogenous peptides involved in the physiologic
regulation of glucose homeostasis. Incretin hormones, including glucagonlike
peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),
are released by the intestine throughout the day, and levels are increased in
response to a meal. When blood glucose concentrations are normal or elevated,GLP-1 and GIP increase the synthesis and release of insulin from pancreatic b
cells via intracellular signaling pathways involving cAMP. GLP-1 also lowers
glucagon secretion from pancreatic αcells, which leads to reduced hepatic
glucose production. | | Originator | Merck (US) | | 使用 | Labeled Sitagliptin , intended for use as an internal standard for the quantification of Sitagliptin by GC- or LC-mass spectrometry. | | 使用 | Sitagliptin is a useful pharmaceutical drug. Could be useful for treating intestinal inflammation, diabetes, pre-?diabetes, impaired glucose tolerance, hepatitis, and?/or inflammatory liver disease. | | 定義 | ChEBI: Sitagliptin is a triazolopyrazine that exhibits hypoglycemic activity. It has a role as a serine proteinase inhibitor, a hypoglycemic agent, an EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor, an environmental contaminant and a xenobiotic. It is a triazolopyrazine and a trifluorobenzene. | | brand name | Januvia | | 臨床応用 | Treatment of type 2 diabetes in combination with
metformin or a thiazolidinedione | | 代謝 | Sitagliptin undergoes minimal metabolism, mainly by the
cytochrome P450 isoenzyme CYP3A4, and to a lesser
extent by CYP2C8.
Renal excretion of sitagliptin involves active tubular
secretion; it is a substrate for organic anion transporter-3
and P-glycoprotein. |
|